PUBLIC COMPANY
saveADARx Pharmaceuticals Inc
founded 2019 · 125 employees · San Diego, CA, USupdated 4mo ago
ADARx Pharmaceuticals is a clinical-stage biotechnology company developing next-generation RNA-targeted therapeutics, including siRNA, antisense, and proprietary RNA editing (EditR) platforms. Its pipeline spans genetic, cardiometabolic, complement-mediated, and central nervous system diseases, with lead programs ADX-324 (hereditary angioedema) and ADX-038 in clinical development.
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- ADARx raises $446M in biotech’s third largest IPO of 2026, City files to go publicTwo RNA biotechs, ADARx Pharmaceuticals and City Therapeutics, are taking advantage of the IPO frenzy, which has led to a total of 27 newly public biotechs so far this year.biospace · 8d ago
- Alnylam alumni lead RNAi biotech City Therapeutics to IPO filingBiotechs are rushing into the IPO queue. City Therapeutics submitted its public pitch late Thursday, the same night ADARx Pharmaceuticals priced its $446 million Nasdaq debut. Kendall Square-based ...endpoints · 8d ago
- ADARx prices $446.3M Nasdaq debut, continuing industry's IPO momentumA buzzy RNAi startup is going public in an upsized $446.3 million Nasdaq listing, adding to the biopharma industry's high IPO velocity. ADARx Pharmaceuticals, the latest entrant onto the public mar…endpoints · 8d ago
- ADARx scores upsized $446M IPO, while fellow RNA biotech City maps out Nasdaq plansADARx Pharmaceuticals has overshot its own IPO ambitions, as fellow RNA-focused biotech City Therapeutics also plans a public listing.fiercebiotech · 8d ago
- RNAi drug specialist ADARx raises $446M IPOADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in more than a decade.biopharma_dive · 9d ago
- 2026 IPO blitz continues with 4 new biotech filingsWith more than 25 companies debuting on the public markets, 2026 has recorded the highest number of biotech IPOs since 2021. Now, four companies—including Iambic Therapeutics and ADARx Pharmaceutic…biospace · 11d ago
- ADARx targets $319M IPO as TRexBio, Retension join filing queueThe fall IPO train is boarding. ADARx Pharmaceuticals, a well-funded siRNA biotech in Phase 3, plans to raise about $318 million in its proposed initial public offering, according to itsendpoints · 12d ago
- Moonwalk reloads with $70M and new RNAi prospects for obesityThe California biotech plans to bring its first drug, enabled by licensing technology from a Chinese drugmaker, into clinical testing for obesity by the end of 2027.biopharma_dive · 25d ago
- AbbVie-backed ADARx plans IPO to bankroll array of clinical-stage siRNA therapiesADARx has reinvigorated its ambitions to go public as the AbbVie-backed biotech looks to fund ongoing clinical trials of a range of next-gen small interfering RNA medicines.fiercebiotech · 27d ago
- AbbVie-allied ADARx aims for IPO with three drugs in the clinicRNA interference company ADARx Pharmaceuticals revealed its intentions to go public in a Friday night SEC filing, trying to take advantage of the industry's IPO momentum. The San Diego biotech plan…endpoints · 28d ago
comments(0)
5-min edit window · permanent after that